Levomilnacipran (Fetzima) is a new SNRI that has been formulated as a once-daily sustained release capsule. It has been approved for the treatment of major depressive disorder in adults based on a randomized controlled trial that compared levomilnacipran (40mg, 80mg, and 120mg) to placebo in 724 adults with major depressive disorder for 2 months. Adverse effects include nausea, constipation, hyperhidrosis, increased heart rate, erectile dysfunction, tachycardia, vomiting, palpitations and urinary hesitation. Levomilnacipran is much more of a norepinephrine reuptake inhibitor than a serotonin reuptake inhibitor, distinguishing it from previously available SNRIs. Do you think levomilnacipran will be a viable addition to the available treatments for MDD?
For more information please see Medscape